chartexchange

CNTX
Context Therapeutics Inc. Common Stock
stockNASDAQ

At CloseOct 2, 2026 3:59:46 PM EDT
0.31USD-1.590%(-0.01)332,647
Pre-marketOct 2, 2026 9:12:30 AM EDT
0.31USD-1.399%(-0.00)
After-hoursOct 2, 2026 4:56:30 PM EDT
0.3148USD+1.745%(+0.0054)
Loading…
Loading…
Healthcare
Biotechnology
HQ
Philadelphia, PA, USA
Previous Close
$0.31
Beta
0.17
52-Week High
$3.62 2026-03-16
52-Week Low
$0.30 2026-09-30
SMA 50
$0.44
SMA 200
$1.57
Avg. Vol 10D
969,633
Avg. Vol 30D
1.50M
Avg. Vol 90D
2.33M
Relative Vol
0.22
64.66M
0.6300%
2,400,000
444
Nov 4, 2026 (30d)
CNTX Profile

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.

CNTX Performance
PeriodPriceDateChangeBeta
1W0.332026-09-28-5.42%3.389
1M0.362026-09-04-14.68%-0.061
3M0.642026-07-06-51.60%0.646
6M2.712026-04-06-88.61%0.223
1Y1.102025-10-03-71.94%0.169
2Y1.922024-10-04-83.93%—
5Y5.102021-10-20-93.95%0.848
CNTX Stock Summary

Context Therapeutics Inc. Common Stock (NASDAQ:CNTX) stock price today is $0.31, and today's volume is 332,647. CNTX is down 1.845% today. The 30 day average volume is 1.50M. CNTX market cap is $28.35M with 91.88M shares outstanding.